WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. The company’s registered capital is 1.242 billion yuan. The company is located in Chengdu Tianfu International Bio-town. WestVac Biopharma has a mature insect cell expressed recombinant protein platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform. The company is committed to the development and production of a variety of innovative vaccines and immunotherapy products.
WestVac Biopharma has built a production base with an annual production capacity of 600 million doses in Chengdu Tianfu International Bio-town. The layout of production line is optimized, the production process is scientific and safe, and the production equipment is basically made in China. The company has completed the construction and verification of GMP production workshop, and obtained the "Drug Manufacturing License". In addition, Guangzhou production base with an annual capacity of 500 million doses is also under construction.
In terms of production, quality, operations management, etc., WestVac Biopharma has introduced advanced talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure that large scale production of vaccines can proceed smoothly.
WestVac Biopharma has also established a good communication with many international organizations such as the World Health Organization (WHO), Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI) and so on. The company has submitted an application for emergency use of COVID-19 vaccine (EUL) to the World Health Organization (WHO), hoping to contribute to global COVID-19 prevention and control.